SCHEMBL5899412

SCHEMBL5899412

O=C(C=C(O)c1nn[nH]n1)c1cn(Cc2ccccn2)cc1CCc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.39
NCEH1 Q6PIU2 1/20 0.39
HDAC1 Q13547 3/20 0.34
HDAC8 Q9BY41 2/20 0.34
ABCB1 P08183 1/20 0.34
HTR1A P08908 1/20 0.34
DRD2 P14416 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
KDM4E B2RXH2 3/20 0.33
HPGD P15428 2/20 0.33
ALDH1A1 P00352 2/20 0.33
ALOX15 P16050 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
LMNA P02545 1/20 0.33
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TAAR1 Q96RJ0 1/20 0.32
PLA2G4A P47712 1/20 0.32
GPR52 Q9Y2T5 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4678751 0.90 KDM4C (0.35) CES1NCEH1HDAC1HDAC8KDM4C
SCHEMBL4676460 0.90 CES1 (0.43) CES1NCEH1HDAC1HDAC8PLA2G4A
SCHEMBL4674218 0.87 CES1 (0.40) CES1NCEH1ABCB1ALDH1A1SMN1; SMN2
SCHEMBL4676558 0.86 ABCB1 (0.36) HDAC1HDAC8ABCB1HTR1ADRD2
SCHEMBL4674328 0.84 CES1 (0.39) CES1NCEH1ALDH1A1TDP1PLA2G4A
SCHEMBL4679350 0.84 CES1 (0.39) CES1NCEH1PLA2G4A
SCHEMBL4674667 0.84 CES1 (0.39) CES1NCEH1HPGDSMN1; SMN2TSHR
SCHEMBL4673837 0.84 CES1 (0.39) CES1NCEH1HDAC1KDM4CKDM4E
SCHEMBL4675233 0.83 CES1 (0.38) CES1NCEH1LMNAPLA2G4A
SCHEMBL4675686 0.83 CES1 (0.38) CES1NCEH1KDM4CALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 CES1 445/4885NCEH1 1046/4885HDAC1 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.